PCI Pharma Services Unveils Major Expansion
Philadelphia-based CDMO, PCI Pharma Services, has committed to substantial investments in sterile fill/finish and drug-device combination assembly across its global operations.
A series of significant infrastructure investments have been revealed by PCI Pharma Services aimed at enhancing its U.S. sterile fill/finish and advanced drug delivery capabilities across its network. The initiative, part of a broader spending commitment surpassing USD 1 billion across U.S. and European operations, targets pharma manufacturers' push for resilient domestic supply chains (1).
PCI’s key investment comes at its San Diego campus, where a USD 100 million project will add a second high-speed isolator filling line for prefilled syringes and cartridges. Scheduled to go operational in 2028, it will double capacity at the site which already supports over 45 FDA-approved products and handles complex injectables like oligonucleotides, peptides, nanoparticles, mRNA, monoclonal antibodies, proteins, and highly potent compounds.
At PCI's Bedford, New Hampshire site, a GMP-ready isolator vial and lyophilization line has been commissioned — capable of 300,000-unit batches at 400 vials per minute - to become amongst the most advanced of its kind in the U.S. A customer-dedicated high-potent sterile fill-finish line is also forthcoming. At both its San Diego and Bedford facilities, the company has invested in cutting-edge automated visual inspection (AVI) systems for sterile fill-finish applications that will support more than 70 million prefilled syringes and cartridges, and 40 million vials per year.
Across its drug-device combination platforms, PCI is partnering with device makers to upgrade autoinjectors and assembly infrastructure in Philadelphia, Pennsylvania, and Rockford, Illinois. A third autoinjector line will be added in 2027 to increase U.S. output to over 250 million units yearly, and feature flexible, high-speed assembly, paired with labeling, secondary packaging, and a dedicated prefilled syringe safety device line.
Finally, PCI is establishing Development Centers of Excellence in Bedford, and Len, Spain, for lyophilization, formulation, analytical support, drug-device combos, long-acting injectables, and ophthalmics that cover potent and non-potent small molecules and biologics in vials, syringes, and cartridges.
“The pharmaceutical industry is at an inflection point, with manufacturers seeking trusted US-based partners to provide scale, expedience, and established quality and compliance track records to support the development and commercialization of next-generation treatments,” said Salim Haffar, CEO of PCI Pharma Services, in a company press release (1). “Backed by over USD 1 billion in global infrastructure investment and decades of operational expertise, PCI’s multi-year journey to bolster its domestic manufacturing footprint allows us to meet growing customer demand for innovative drug product and drug delivery solutions, toward the evergreen goal of delivering life-changing therapies to patients (1).”
Reference
PCI Pharma Services. Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities. Press release, April 27, 2026.